iae0972
Recombinant proteinexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Jun 1, 2022 (NCT05396339)
Timeline
Indications
Mechanism of action
- Epidermal growth factor receptor erbB1BINDING AGENT
EGFR binding agent
Chemistry & pharmacology
- Payload
- IL-10
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06719479 | Phase 2/Phase 3 (Phase 3) | Jan 1, 2025 | SUNHO（China）BioPharmaceutical CO., Ltd. |
| NCT05396339 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2022 | Huazhong University of Science and Technology, Shandong first medical University, SUNHO（China）BioPharmaceutical CO., Ltd. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| SUNHO（China）BioPharmaceutical CO., Ltd. | For profit | 2 | 2 | 2 | 2022 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Shandong first medical University | Academic/Hospital | 1 | 0 | 1 | 2022 |
3 organizations
Page 1 / 1